JP2016504378A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504378A5 JP2016504378A5 JP2015551223A JP2015551223A JP2016504378A5 JP 2016504378 A5 JP2016504378 A5 JP 2016504378A5 JP 2015551223 A JP2015551223 A JP 2015551223A JP 2015551223 A JP2015551223 A JP 2015551223A JP 2016504378 A5 JP2016504378 A5 JP 2016504378A5
- Authority
- JP
- Japan
- Prior art keywords
- ylmethyl
- carboxylic acid
- aryl
- aminomethyl
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *c1nc(-c2ccccc2)ccc1 Chemical compound *c1nc(-c2ccccc2)ccc1 0.000 description 4
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750074P | 2013-01-08 | 2013-01-08 | |
| GBGB1300304.1A GB201300304D0 (en) | 2013-01-08 | 2013-01-08 | Benzylamine derivatives |
| GB1300304.1 | 2013-01-08 | ||
| US61/750,074 | 2013-01-08 | ||
| US201361865732P | 2013-08-14 | 2013-08-14 | |
| US61/865,732 | 2013-08-14 | ||
| PCT/GB2014/050043 WO2014108679A1 (en) | 2013-01-08 | 2014-01-08 | Benzylamine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504378A JP2016504378A (ja) | 2016-02-12 |
| JP2016504378A5 true JP2016504378A5 (enExample) | 2017-02-09 |
| JP6430398B2 JP6430398B2 (ja) | 2018-11-28 |
Family
ID=47748123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551223A Expired - Fee Related JP6430398B2 (ja) | 2013-01-08 | 2014-01-08 | ベンジルアミン誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9670157B2 (enExample) |
| EP (1) | EP2943483B1 (enExample) |
| JP (1) | JP6430398B2 (enExample) |
| KR (1) | KR102185928B1 (enExample) |
| CN (1) | CN105143201B (enExample) |
| AU (1) | AU2014204666B2 (enExample) |
| BR (1) | BR112015016293B1 (enExample) |
| CA (1) | CA2897273C (enExample) |
| ES (1) | ES2623895T3 (enExample) |
| GB (1) | GB201300304D0 (enExample) |
| HU (1) | HUE033243T2 (enExample) |
| MX (1) | MX362889B (enExample) |
| MY (1) | MY182590A (enExample) |
| NZ (1) | NZ709609A (enExample) |
| PL (1) | PL2943483T3 (enExample) |
| RU (1) | RU2660421C2 (enExample) |
| SG (1) | SG11201505309TA (enExample) |
| WO (1) | WO2014108679A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6033319B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| EP2906552B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| US9403774B2 (en) | 2012-10-12 | 2016-08-02 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| TR201807316T4 (tr) | 2012-10-12 | 2018-06-21 | Bristol Myers Squibb Co | Bir faktör XIa inhibitörünün kristalli formları. |
| WO2014160668A1 (en) | 2013-03-25 | 2014-10-02 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
| GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| HUE14755117T2 (hu) * | 2013-08-14 | 2018-12-28 | Kalvista Pharmaceuticals Ltd | Plazma-kallikrein inhibitorok |
| NO2760821T3 (enExample) | 2014-01-31 | 2018-03-10 | ||
| SG10201908467RA (en) | 2014-01-31 | 2019-10-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| ES2714283T3 (es) | 2014-09-04 | 2019-05-28 | Bristol Myers Squibb Co | Macrociclos de diamida que son inhibidores de FXIa |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| GB201421085D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| DK4019022T3 (en) | 2015-10-01 | 2024-02-19 | Biocryst Pharm Inc | Human plasma kallikrein inhibitors |
| GB201609519D0 (en) * | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
| DK3464271T3 (da) * | 2016-05-31 | 2020-06-15 | Kalvista Pharmaceuticals Ltd | Pyrazolderivater som plasma-kallikreininhibitorer |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| US11168080B2 (en) | 2017-04-26 | 2021-11-09 | Mitobridge, Inc. | Dynamin-1-like protein inhibitors |
| PT3716952T (pt) * | 2017-11-29 | 2022-04-14 | Kalvista Pharmaceuticals Ltd | Formas de administração que incluem um inibidor de calicreína plasmática |
| GB201719882D0 (en) * | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| GB201910125D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
| GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021032935A1 (en) | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| CN114286820A (zh) | 2019-08-21 | 2022-04-05 | 卡尔维斯塔制药有限公司 | 酶抑制剂 |
| GB201918994D0 (en) | 2019-12-20 | 2020-02-05 | Kalvista Pharmaceuticals Ltd | Treatments of diabetic macular edema and impaired visual acuity |
| GB2591730A (en) | 2019-12-09 | 2021-08-11 | Kalvista Pharmaceuticals Ltd | New polymorphs |
| RU2734970C1 (ru) * | 2019-12-10 | 2020-10-26 | Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Фармасофт" | Система доставки 2-этил-6-метил-3-гидроксипиридина сукцината для перорального применения в форме гастроретентивной таблетки |
| CN115210229A (zh) | 2020-01-03 | 2022-10-18 | 博格有限责任公司 | 多环酰胺作为治疗癌症的ube2k调节剂 |
| TWI873290B (zh) | 2020-02-13 | 2025-02-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| KR20230038526A (ko) | 2020-07-10 | 2023-03-20 | 머크 샤프 앤드 돔 엘엘씨 | 혈장 칼리크레인 억제제 |
| WO2022079446A1 (en) | 2020-10-15 | 2022-04-21 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
| EP4232031A1 (en) | 2020-10-23 | 2023-08-30 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
| JP2024505596A (ja) | 2021-02-09 | 2024-02-06 | カルビスタ・ファーマシューティカルズ・リミテッド | 遺伝性血管性浮腫の治療 |
| CN115073429A (zh) * | 2021-03-15 | 2022-09-20 | 昆药集团股份有限公司 | 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法 |
| WO2023002219A1 (en) | 2021-07-23 | 2023-01-26 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
| WO2023185634A1 (zh) * | 2022-03-30 | 2023-10-05 | 南京明德新药研发有限公司 | 作为血浆激肽释放酶抑制剂的杂环类化合物 |
| EP4480545A3 (en) | 2022-04-27 | 2025-02-26 | Kalvista Pharmaceuticals Limited | Formulations of a plasma kallikrein inhibitor |
| WO2024180100A1 (en) | 2023-02-27 | 2024-09-06 | Kalvista Pharmaceuticals Limited | New solid form of a plasma kallikrein inhibitor |
| WO2025153806A1 (en) | 2024-01-15 | 2025-07-24 | Kalvista Pharmaceuticals Limited | Methods for determining amidolytic activity |
| WO2025172693A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
| WO2025172692A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| US7101878B1 (en) * | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
| HUP0103622A3 (en) * | 1998-08-20 | 2003-01-28 | Agouron Pharmaceuticals Inc La | Non-peptide gnrh agents, methods and intermediates for their preparation and medicaments containing them |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
| US7247654B2 (en) * | 2003-06-04 | 2007-07-24 | Bristol-Myers Squibb Company | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| EP1966141A1 (en) * | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| NZ568595A (en) * | 2005-12-14 | 2010-04-30 | Bristol Myers Squibb Co | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors |
| WO2008016883A2 (en) * | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| EP2259679A4 (en) | 2008-01-31 | 2011-09-14 | Joslin Diabetes Ct | METHODS OF TREATING KALLIKREIN RELATED DISORDERS |
| WO2009106980A2 (en) | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
| US8324199B2 (en) | 2008-03-13 | 2012-12-04 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
| AU2010330743A1 (en) | 2009-12-18 | 2012-07-05 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| MX345259B (es) | 2010-01-28 | 2017-01-23 | The Medicines Company (Leipzig) Gmbh | Inhibidores de serina proteasas similares a tripsina, y su preparación y uso. |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| WO2012004678A2 (en) | 2010-07-07 | 2012-01-12 | The Medicines Company (Leipzig) Gmbh | Serine protease inhibitors |
| US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| WO2012142080A1 (en) * | 2011-04-12 | 2012-10-18 | Bristol-Myers Squibb Company | Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors |
| WO2012142308A1 (en) * | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| WO2012174362A1 (en) | 2011-06-17 | 2012-12-20 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| US20140378474A1 (en) * | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| CA2894642A1 (en) | 2013-01-08 | 2014-07-17 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
-
2013
- 2013-01-08 GB GBGB1300304.1A patent/GB201300304D0/en not_active Ceased
-
2014
- 2014-01-08 CA CA2897273A patent/CA2897273C/en active Active
- 2014-01-08 BR BR112015016293-2A patent/BR112015016293B1/pt not_active IP Right Cessation
- 2014-01-08 NZ NZ709609A patent/NZ709609A/en not_active IP Right Cessation
- 2014-01-08 JP JP2015551223A patent/JP6430398B2/ja not_active Expired - Fee Related
- 2014-01-08 EP EP14700111.9A patent/EP2943483B1/en active Active
- 2014-01-08 WO PCT/GB2014/050043 patent/WO2014108679A1/en not_active Ceased
- 2014-01-08 SG SG11201505309TA patent/SG11201505309TA/en unknown
- 2014-01-08 MY MYPI2015702197A patent/MY182590A/en unknown
- 2014-01-08 AU AU2014204666A patent/AU2014204666B2/en not_active Ceased
- 2014-01-08 MX MX2015008835A patent/MX362889B/es active IP Right Grant
- 2014-01-08 CN CN201480011941.3A patent/CN105143201B/zh not_active Expired - Fee Related
- 2014-01-08 PL PL14700111T patent/PL2943483T3/pl unknown
- 2014-01-08 RU RU2015133171A patent/RU2660421C2/ru active
- 2014-01-08 KR KR1020157021439A patent/KR102185928B1/ko not_active Expired - Fee Related
- 2014-01-08 US US14/759,542 patent/US9670157B2/en not_active Expired - Fee Related
- 2014-01-08 ES ES14700111.9T patent/ES2623895T3/es active Active
- 2014-01-08 HU HUE14700111A patent/HUE033243T2/hu unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504378A5 (enExample) | ||
| RU2015133171A (ru) | Бензиламиновые производные | |
| JP2016519156A5 (enExample) | ||
| RU2015154987A (ru) | Гетероциклические производные | |
| RU2017122364A (ru) | N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина | |
| DK2531191T3 (en) | Sigma ligands for use in the prevention and / or treatment of post-operative pain | |
| RU2455288C2 (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| RU2020140891A (ru) | Производные пиразола в качестве ингибиторов калликреина | |
| JP2019077725A5 (enExample) | ||
| RU2018140092A (ru) | Новые пиразолпиримидиновые производные | |
| JP2016530262A5 (enExample) | ||
| DK3009426T3 (en) | 4-ALKYNYL-IMIDAZOLE DERIVATIVE AND MEDICINE COMPREHENSIVE AS AN ACTIVE INGREDIENT | |
| CN102971291B (zh) | 新型酰胺衍生物及其作为药物的用途 | |
| JP2016528245A5 (enExample) | ||
| AR045389A1 (es) | Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido | |
| RU2009117705A (ru) | Производные 2-аминокарбонилпиридина | |
| RU2016108753A (ru) | Ингибиторы ферментов | |
| JP2015535834A5 (enExample) | ||
| RU2011140869A (ru) | Пиперазиновое соединение, ингибирующее простагландин-d-синтазу | |
| RU2014142328A (ru) | Производные пиперидина в качестве агонистов gpr119 | |
| RU2016112542A (ru) | Новые активаторы растворимой гуанилатциклазы и их применение | |
| JP2016540811A5 (enExample) | ||
| KR20180015262A (ko) | 피라졸 유도체, 또는 그 약리학적으로 허용되는 염 | |
| JP2013535414A5 (enExample) | ||
| JP2018515489A5 (enExample) |